Enterome - Model EO2401 -Microbiome-Based Drugs

EO2401 comprises three OncoMimics, which are strongly homologous but not identical to three key tumor antigens that are highly expressed in human malignancies, including glioblastoma (GBM) and adrenal tumors.

Two Phase 1b/2a clinical trials investigating EO2401 in combination with a checkpoint inhibitor for the treatment of glioblastoma (ROSALIE study, NCT04116658) and of adrenal tumors (SPENCER study, NCT04187404) were initiated mid2020.